Acquired MACRILEN (macimorelin) from Aeterna Zentaris for the diagnosis of Adult Growth Hormone Deficiency
Last patient enrolled (LPI) in phase 3 SONICS trial of RECORLEV (levoketoconazole) for endogenous Cushing's syndrome
Launched KEVEYIS (dichlorphenamide) for Primary Periodic Paralysis
Acquired KEVEYIS (dichlorphenamide) from Taro Pharmaceutical Industries for Primary Periodic Paralysis
Acquired veldoreotide, being studied for acromegaly, from Aspireo Pharmaceuticals
First patient enrolled in phase 3 SONICS trial of RECORLEV in endogenous Cushing's syndrome
RECORLEV received EU orphan drug designation
RECORLEV received US orphan drug designation
Pivoted RECORLEV focus from diabetes to Cushing's syndrome
© 2018 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MACRILEN™ is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.
MLR-0010 V13 01/2018